ArticleTranslational cancer research2020
Effect of breast cancer as the first or second primary cancer on the prognosis of women with thyroid cancer: a SEER database analysis.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Breast cancer as the first primary malignancy: clinical pathological characteristics of common cancer combinations.Discover oncology · 2025Review
- Risk factors for secondary thyroid cancer in patients with breast cancer: a propensity‑matched SEER analysis.Scientific reports · 2024Article
- Association Between a History of Breast Cancer and Decreased Thyroid Cancer-specific Mortality.The Journal of clinical endocrinology and metabolism · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough many studies have evaluated the association between breast cancer (BC) and thyroid cancer (TC), this association has not been completely studied. In this study, we focused on the effect of BC as the first or second primary cancer on survival among women with TC. We present the following article in accordance with the STROBE reporting checklist.
methodsUsing the Surveillance, Epidemiology, and End Results (SEER) database, we performed a retrospective cohort analysis of 134,785 women with BC and TC between 1974 and 2016. The patients were divided into three subgroups, namely, TC only (TC group, n=128,888), BC after TC (TC2BC group, n=3,000), and BC before TC (BC2TC group, n=2,897). The curves for overall survival (OS) and cancer-specific survival (CSS) were evaluated, and Cox regression analyses were performed to examine the effect of BC as the first and second primary cancer on the CSS and OS of TC patients.
resultsThe CSS rates in the TC, TC2BC, and BC2TC groups were 96.96%, 98.70%, and 96.70%, respectively, and the OS rates were 91.17%, 77.13%, and 78.63%, respectively. Using the TC group as a reference, the hazard ratios (HRs) for the CSS of the TC2BC and BC2TC groups were 0.333 [95% confidence interval (CI): 0.243-0.456, P<0.001] and 1.299 (95% CI: 1.062-1.589, P=0.011), respectively. The corresponding HRs for the OS were 1.544 (95% CI: 1.428-1.668, P<0.001) and 3.429 (95% CI: 3.158-3.724, P<0.001), respectively.
conclusionsAmong the female patients with TC, BC, as the second primary cancer, has a significant protective effect on the CSS of TC patients; however, when BC is the first primary cancer, it is a risk factor. Besides, BC is a risk factor for the OS of TC patients, especially for patients who develop TC after BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.